Based on our retrospective observation of 21 AIS patients with a history of CHD and no prior use of PCSK9 inhibitors, hospitalized at the First Affiliated Hospital of Dalian Medical University from April 2022 to June 2023, a total of 7 patients exhibited END within 24 h to 7 days of disease onset, accounting for 33.3%. Here, PCSK9 is linked to androgen insensitivity syndrome.